ZFGN Zafgen Inc.

2.5
-0.09  -3%
Previous Close 2.59
Open 2.57
Price To Book 1
Market Cap 93287795
Shares 37,315,118
Volume 156,633
Short Ratio
Av. Daily Volume 304,793

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data from second cohort released January 17, 2019.
ZGN-1061
Diabetes
Announced July 2016 suspension of development of Beloranib
Beloranib
Severe obesity
Announced July 2016 suspension of development of Beloranib
Beloranib
Prader-Willi Syndrome (PWS)
Announced July 2016 suspension of development of Beloranib
Beloranib
Severe obesity

Latest News

  1. Zafgen, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
  2. Edited Transcript of ZFGN earnings conference call or presentation 11-Mar-19 9:00pm GMT
  3. Lifshitz & Miller LLP Announces Investigation of Amyris, Inc., iRhythm Technologies, Inc., Orion Group Holdings, Inc., Osmotica Pharmaceuticals plc, Quantenna Communications, Inc., WABCO Holdings, Inc. and Zafgen, Inc.
  4. INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Zafgen, Inc. Investors
  5. Glancy Prongay & Murray LLP Announces Investigation on Behalf of Zafgen, Inc. Investors
  6. What Do Investors Need To Know About Zafgen, Inc.’s (NASDAQ:ZFGN) Growth?
  7. Zafgen to Present at the 31st Annual ROTH Conference
  8. Biotech Stock Roundup: REGN Gets FDA Nod for Dupixent & Other Pipeline News
  9. The Daily Biotech Pulse: Zafgen Won't File IND For Metabolic Disorder Drug, Positive Results For Akebia's Anemia Drug
  10. Zafgen shelves another drug; chief medical officer exits
  11. Zafgen: 4Q Earnings Snapshot
  12. Zafgen Reports Fourth Quarter and Full Year 2018 Operating and Financial Results and Provides Key Program and Business Updates
  13. Zafgen to Present at the Cowen and Company 39th Annual Health Care Conference
  14. Zafgen to Host Conference Call to Discuss Fourth Quarter and Full Year 2018 Financial Results
  15. Zafgen, Inc. Strengthens Executive Leadership Team with Appointment of Industry Veteran Priya Singhal as Head of Research and Development
  16. Latest data on Zafgen's diabetes pill does little to soothe investors
  17. Zafgen Announces Positive Results for Second Cohort of Phase 2 Clinical Trial of ZGN-1061
  18. Zafgen Enters Oversold Territory